Targeting the heart with gene therapy-optimized gene delivery methods.

Area of Science:

• Molecular and cellular cardiology
• Cardiovascular research
• Gene therapy

Background:

• Cardiac gene therapy is an emerging field with ongoing clinical investigations.
• Various vector systems, including non-viral and viral, have been developed for cardiac gene delivery.
• Challenges remain regarding transfection efficiency, gene expression duration, organ specificity, and immunogenicity.

Purpose of the Study:

• To provide a comprehensive overview of gene delivery strategies for cardiac applications.
• To review different vector systems and their characteristics in cardiac gene therapy.
• To discuss advancements in targeting and delivery techniques for improved efficiency.

Main Methods:

• Review of experimental and clinical studies on cardiac gene therapy.
• Analysis of non-viral vectors (e.g., plasmid DNA) and viral vectors (e.g., adenoviral, adeno-associated virus).
• Evaluation of transcriptional and transductional targeting strategies, and application techniques (e.g., intramyocardial injection, perfusion).

Main Results:

• Non-viral vectors offer organ specificity but have limitations in efficiency and expression.
• Viral vectors, particularly improved adeno-associated virus serotypes, show higher transduction rates.
• Enhanced targeting and delivery methods can improve vector efficiency and reduce required titers.

Conclusions:

• Significant progress has been made in cardiac gene therapy vector development and delivery.
• Adeno-associated virus vectors, with enhanced serotypes and targeting, represent a promising approach.
• Further optimization of gene delivery strategies is crucial for successful clinical translation in cardiovascular medicine.